WT1 Expression in Patients with Myelodysplastic Syndromes: A Variety of Possibilities in Future al kali Practice

被引：1
|
作者：
Ogata, Kiyoyuki [1 ]
机构：
[1] Metropolitan Res & Treatment Ctr Blood Disorders, Tokyo, Japan
来源：
ACTA HAEMATOLOGICA | 2017年 / 137卷 / 01期
关键词：
TUMOR GENE WT1; PERIPHERAL-BLOOD; MESSENGER-RNA; BONE-MARROW; CELLS;
D O I：
10.1159/000449363
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：30 / 31
页数：2
相关论文
共 50 条
  • [41] A new method of Wilms' tumor gene WT1 quantitative assay (WT1 assay) based on real-time PCR for the detection of minimal residual disease (MRD) in patients with leukemia and myelodysplastic syndromes (MDS)
    Tamaki, H
    Ogawa, H
    Oka, Y
    Soma, T
    Sugiyama, H
    LEUKEMIA, 2001, 15 (12) : 2024 - 2024
  • [42] STUDY OF EXPRESSION OF THE WT1 GENE IN PERIPHERAL BLOOD OF PATIENTS WITH MYELODYSPLASIC SYNDROMES. RELATIONSHIP WITH CLINICAL AND BIOLOGICAL VARIABLES
    Campos, Davo E.
    Anton, A.
    Pinero, Romero P.
    Marco, Vera P.
    Garcia, Hernandez C.
    Garzo, Moreno A.
    Vasquez, C.
    Manresa, P.
    Lopez, Castano F.
    Suarez, M.
    Amoros, C.
    Costa, S.
    Lopez, Cedeno T.
    Jimenez, Esteso M.
    Diaz, Rodriguez, V
    Blazquez, L.
    Ruiz, Sogorb P.
    Cobo, J.
    Molla, M. A.
    Tarin, F.
    HAEMATOLOGICA, 2020, 105 : 182 - 183
  • [43] PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes
    Qin, Ya-Zhen
    Zhu, Hong-Hu
    Liu, Yan-Rong
    Wang, Ya-Zhe
    Shi, Hong-Xia
    Lai, Yue-Yun
    Xu, Lan-Ping
    Liu, Dai-Hong
    Jiang, Qian
    Li, Ling-Di
    Jiang, Bin
    Liu, Kai-Yan
    Huang, Xiao-Jun
    LEUKEMIA & LYMPHOMA, 2013, 54 (07) : 1442 - 1449
  • [44] Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome
    Yasukawa, Masaki
    Fujiwara, Hiroshi
    Ochi, Toshiki
    Suemori, Koichiro
    Narumi, Hiroshi
    Azuma, Taichi
    Kuzushima, Kivotaka
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (05) : 314 - 315
  • [45] Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes
    Allampallam, K
    Shetty, V
    Hussaini, S
    Mazzoran, L
    Zorat, F
    Huang, RW
    Raza, A
    ANTICANCER RESEARCH, 1999, 19 (6B) : 5323 - 5328
  • [46] No significant expression of Wt1 gene in multiple myeloma patients at diagnosis: Is Wt1 gene expression useful marker for minimal residual disease in multiple myeloma?
    Ozkul, Yusuf
    Caglayan, Ahmet O.
    Kocyigit, Ismail
    Saatci, Cetin
    Akalin, Hilal
    Demir, Muzaffer
    Altuntas, Fevzi
    Cetin, Mustafa
    Eser, Bulent
    Kaynar, Leylagul
    BLOOD, 2007, 110 (11) : 263B - 263B
  • [47] Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients
    Chiba, Yasuyoshi
    Hashimoto, Naoya
    Tsuboi, Akihiro
    Rabo, Carter
    Oka, Yoshihiro
    Kinoshita, Manabu
    Kagawa, Naoki
    Oji, Yusuke
    Sugiyama, Haruo
    Yoshimine, Toshiki
    BRAIN TUMOR PATHOLOGY, 2010, 27 (01) : 29 - 34
  • [48] Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy
    Chisato Yokota
    Naoki Kagawa
    Koji Takano
    Yasuyoshi Chiba
    Manabu Kinoshita
    Noriyuki Kijima
    Yusuke Oji
    Yoshihiro Oka
    Haruo Sugiyama
    Akihiro Tsuboi
    Shuichi Izumoto
    Haruhiko Kishima
    Naoya Hashimoto
    Cancer Immunology, Immunotherapy, 2022, 71 : 189 - 201
  • [49] Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients
    Yasuyoshi Chiba
    Naoya Hashimoto
    Akihiro Tsuboi
    Carter Rabo
    Yoshihiro Oka
    Manabu Kinoshita
    Naoki Kagawa
    Yusuke Oji
    Haruo Sugiyama
    Toshiki Yoshimine
    Brain Tumor Pathology, 2010, 27 : 29 - 34
  • [50] Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).
    Breccia, Massimo
    Latagliata, Roberto
    Cannella, Laura
    Carmosino, Ida
    Gottardi, Enrico
    Cilloni, Daniela
    Vignetti, Marco
    Santopietro, Michelina
    Mancini, Marco
    Alimena, Giuliana
    BLOOD, 2009, 114 (22) : 707 - 707
12345